Biotech Calendar: Key FDA Action Dates
Allos Therapeutics (ALTH)
Drug/indication: Pralatrexate for peripheral T-cell lymphoma
FDA decision date: Sept. 24
Allos expects the FDA to convene an advisory panel meeting to review pralatrexate, although a meeting has not been formally announced. The scheduling of the advisory meeting may delay the FDA's approval decision.
Drug/indication: Denosumab for osteoporosis
FDA advisory panel date: Aug. 13
FDA decision date: Oct. 19
Denosumab is the most important drug in the company's late-stage pipeline. Approval for osteoporosis, and later for certain cancer indications, could re-invigorate earnings growth after a couple of flat years. Denosumab's safety profile will be the focus of the Aug. 13 advisory panel meeting.Acorda Therapeutics (ACOR)
Drug/indication: Fampridine for multiple sclerosis
FDA decision date: Oct. 22 Fampridine improves nerve function and is being developed to improve the walking abilities of patients with multiple sclerosis. GTx (GTXI)
Drug/indication: Acapodene for prostate cancer
FDA decision date: Oct. 30 Acapodene is designed to reduce bone fractures in prostate cancer patients being treated with androgen deprivation therapy. Transcept Pharmaceuticals (TSPT)
Drug/indication: Intermezzo for insomnia
FDA decision date: Oct. 30 Intermezzo is a dissolvable, low-dose form of the sleep aid Ambien which will be marketed for people who awake in the middle of the night but can't fall back to sleep. Cadence Pharmaceuticals (CADX)
Drug/indication: Acetevance for acute pain/fever
FDA decision date: Nov. 13 Acetevance is an injectable form of the painkiller acetaminophen for use in hospitals. Somaxon Pharmaceuticals (SOMX)
Drug/indication: Silenor for insomnia
FDA decision date: Dec. 4 The FDA refused to approve Silenor last February, requesting additional clinical information from Somaxon. The company resubmitted Silenor in June.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV